The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Limited (Orchid) has informed that it has received approval from the USFDA for its ANDA
(Abbreviated New Drug Application) for Amlodipne Besylate Tablets 2.5 mg, 5mg and 10mg.

Amlodipine Besylate Tablests falls under the Central Nervous System (CNS) therapeutic segment and is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients.

With this approval, Orchid's cumulative ANDA approval counts stands at 32 and the total ANDA filing count stands at 58. Sharekhan, one of the leading broking cum researching house, has maintained its buy rating on Orchid Chemical, with price target of Rs 163, in its report dated July 1, 2009. The scrip of the company today closed at Rs 96, marginally up compared to its previous close.